Withdrawal of nifedipine capsules: jeopardizing the treatment of acute severe hypertension in pregnancy? Australasian Society for the Study of Hypertension in Pregnancy.
Short-acting oral nifedipine has been withdrawn from the Australian market because of reports of its adverse effects after long-term treatment in non-pregnant patients with heart disease. This will have a major impact on the treatment of acutely hypertensive pregnant women, in whom the drug has proven to be safe, effective and easy to administer. Should pregnant women be forced to use less suitable agents, thus threatening their own and their babies' health?
Brown
M A
MA
Department of Medicine, St George Hospital, Kogarah, NSW.
McCowan
L M
LM
North
R A
RA
Walters
B N
BN
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001315:Australia; D005260:Female; D006801:Humans; D007880:Legislation, Drug; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use; D011225:Pre-Eclampsia / Q000188:drug therapy*; D011247:Pregnancy; D018570:Risk Assessment; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use
D000959:Antihypertensive Agents; D014665:Vasodilator Agents; D009543:Nifedipine